CRL Charles River Laboratories International Inc.

Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program

Charles River Laboratories International, Inc. (NYSE: CRL) recently opened the first Charles River Accelerator and Development Lab (CRADL®) location in Chicago, expanding contract vivarium space for the biopharmaceutical industry in Illinois.

is located in , in the heart of Chicago’s Fulton Market, which is quickly emerging as a hub of the local life sciences community. Fulton Labs also includes premier wet and dry laboratory and office space, offered by Portal Innovations. By offering on-demand facilities, both emerging and established biopharmaceutical companies and research institutions are able to quickly start new projects, accelerating the early stage of research. This allows scientists to focus on research, while leaving the animal husbandry and daily vivarium management to a trusted partner.

The Combined Expertise and Reach of Explora BioLabs and CRADL

With the in April 2022, the CRADL-Explora Vivarium Network was established as a premier partner for clients to launch or expand their drug research programs, with the added benefit of access to Charles River’s complete portfolio of integrated drug discovery and non-clinical development resources. The CRADL-Explora Vivarium Network operates 28 vivarium facilities, providing over 380,000 square feet of turnkey rental capacity in key biohubs, including Massachusetts, California, Washington, Shanghai, London, and now Illinois. This network supports the growth of the entire biotech ecosystem in each city, allowing researchers to rapidly engage in their research while maintaining the flexibility to relocate or co-locate, knowing they will have reliable, high-quality facilities nearby.

Approved Quotes

  • “Chicago is emerging as a key biohub in the United States, with a growing life sciences community. By providing contract vivarium services, we’re able to support clients in starting projects quickly, without the burden of building infrastructure, which can be costly and time consuming.” –Colin Dunn, Ph.D., Corporate Senior Vice President, Global Research Models & Services, Charles River
  • "Charles River has the largest network of contract vivarium facilities globally, and we're thrilled to have one at our Fulton Market location. Their depth of experience provides an incredible opportunity for the life sciences community in Chicago and other biotech communities. We're glad to have established a relationship with a world-class organization like Charles River, and we look forward to working together in the future.” —John Flavin, Founder and CEO, Portal Innovations

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit

EN
28/11/2022

Underlying

Reports on Charles River Laboratories International Inc.

Charles River Laboratories Int'l, Inc.: Update to credit analysis

Charles River's credit profile reflects its strong and consistent free cash flow, offset by its sensitivity to R&D budgets of clients and research funding availability.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 December 2025 in which we reassessed the appropriateness of the r...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch